HTFL (Heartflow, Inc. Common Stock) Stock Analysis - News

Heartflow, Inc. Common Stock (HTFL) is a publicly traded the market company. As of May 21, 2026, HTFL trades at $27.38 with a market cap of $2.21B and a P/E ratio of -8.61. HTFL moved +3.08% today. Year to date, HTFL is -9.96%; over the trailing twelve months it is flat. Its 52-week range spans $20.13 to $41.22. Analyst consensus is strong buy with an average price target of $37.00. Rallies surfaces HTFL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in HTFL news today?

Heartflow Data Shows 4x Risk from High Plaque Volume, NAVIGATE-PCI Registry Starts: Heartflow presented data from a 15,000-patient registry showing high plaque volume predicts a fourfold increase in major adverse cardiovascular events regardless of risk factors or stenosis severity. It enrolled the first patient in its 5,000-patient NAVIGATE-PCI Registry to test AI-guided CT planning’s effect on clinical strategy and physician confidence.

HTFL Key Metrics

Key financial metrics for HTFL
MetricValue
Price$27.38
Market Cap$2.21B
P/E Ratio-8.61
EPS$-3.17
Dividend Yield0.00%
52-Week High$41.22
52-Week Low$20.13
Volume558
Avg Volume0
Revenue (TTM)$176.03M
Net Income$-116.79M
Gross Margin76.80%

Latest HTFL News

Recent HTFL Insider Trades

  • Rogers Campbell sold 9.22K (~$261.27K) on May 18, 2026.
  • Farquhar John C.M. sold 22.56K (~$657.01K) on May 11, 2026.
  • Bain Capital Life Sciences Investors, LLC sold 892.53K (~$26.04M) on Apr 30, 2026.

HTFL Analyst Consensus

7 analysts cover HTFL: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $37.00.

Common questions about HTFL

What changed in HTFL news today?
Heartflow Data Shows 4x Risk from High Plaque Volume, NAVIGATE-PCI Registry Starts: Heartflow presented data from a 15,000-patient registry showing high plaque volume predicts a fourfold increase in major adverse cardiovascular events regardless of risk factors or stenosis severity. It enrolled the first patient in its 5,000-patient NAVIGATE-PCI Registry to test AI-guided CT planning’s effect on clinical strategy and physician confidence.
Does Rallies summarize HTFL news?
Yes. Rallies summarizes HTFL news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is HTFL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HTFL. It does not provide personalized investment advice.
HTFL

HTFL